Literature DB >> 16485097

[Treatment options in chronic hepatitis B].

S Nitschmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16485097     DOI： 10.1007/s00108-005-1573-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  5 in total

1.  A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.

Authors:  Henry Lik-Yuen Chan; Nancy Wai-Yee Leung; Alex Yui Hui; Vincent Wai-Sun Wong; Choong-Tsek Liew; Angel Mei-Ling Chim; Francis Ka-Leung Chan; Lawrence Cheung-Tsui Hung; Yuk-Tong Lee; John Siu-Lun Tam; Christopher Wai-Kei Lam; Joseph Jao-Yiu Sung
Journal:  Ann Intern Med       Date:  2005-02-15       Impact factor: 25.391

2.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Authors:  Harry L A Janssen; Monika van Zonneveld; Hakan Senturk; Stefan Zeuzem; Ulus S Akarca; Yilmaz Cakaloglu; Christopher Simon; Thomas M K So; Guido Gerken; Robert A de Man; Hubert G M Niesters; Pieter Zondervan; Bettina Hansen; Solko W Schalm
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

3.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Authors:  George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

4.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

5.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.

Authors:  C Niederau; T Heintges; S Lange; G Goldmann; C M Niederau; L Mohr; D Häussinger
Journal:  N Engl J Med       Date:  1996-05-30       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.